Cost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A | Zendy

Farhad Hosseinzadeh Lotfı | Zendy; Hamid Talebianpour | Zendy; Khosro Keshavarz | Zendy; Fatemeh Emadi | Zendy; Mohammadreza Bordbar | Zendy; Peivand Bastani | Zendy

Open Access

Cost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A

Author(s) -

Farhad Hosseinzadeh Lotfı,

Hamid Talebianpour,

Khosro Keshavarz,

Fatemeh Emadi,

Mohammadreza Bordbar,

Peivand Bastani

Publication year - 2020

Publication title -

daru journal of pharmaceutical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.645

H-Index - 42

eISSN - 2008-2231

pISSN - 1560-8115

DOI - 10.1007/s40199-020-00347-8

Subject(s) - recombinant dna , medicine , pharmacology , chemistry , biochemistry , gene

Hemophilia is known as one of the most common coagulation disorders whose treatment costs are particularly high in developing countries, and about 90% of them are related to factor VIII (FVIII) and direct medical costs (DMCs). Thus, the present study aimed to analyze cost-utility of two FVIII diet therapies prepared using blood plasma and recombinant technique.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research